15 results
DEFA14A
CVM
Cel-Sci Corp.
7 Mar 24
Additional proxy soliciting materials
11:33am
% in the control at 5 years
28.6% absolute 5-year overall survival benefit versus control; statistically significant p = 0.0015 and hazard ratio = 0.35
Tumor
424B5
CVM
Cel-Sci Corp.
9 Feb 24
Prospectus supplement for primary offering
8:44am
control (p=0.0015);
0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);35% rate of pre-surgery reductions and/or downstages (p<0.01 … to the potential positive effects of Multikine.
Another measure of survival benefit is called the “hazard ratio,” which compares the chances of dying
S-8
EX-99
CVM
Cel-Sci Corp.
22 Dec 23
Registration of securities for employees
4:01pm
benefit versus control (p=0.0015);
0.349 hazard ratio vs control (95% CIs [0.18, 0.66], Wald p=0.0012);35% rate of pre-surgery reductions … to the potential positive effects of Multikine.
Another measure of survival benefit is called the “hazard ratio,” which compares the chances of dying
424B5
6fxha nhg21m
16 Nov 23
Prospectus supplement for primary offering
8:39am
8-K
EX-99.1
wu1p8b r3rxgq
30 Oct 23
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-99
z7ov8r
24 Oct 23
Other Events
10:18am
8-K
EX-99
yw46t2ifb4ypjg
12 Jul 23
Other Events
9:01am
8-K
EX-99.1
r6pgxjmvd7p9
22 Aug 22
Cel-sci Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.Gov
9:00am
8-K
EX-99
ql6zw9wvi35qn
7 Jul 21
Other Events
3:24pm
- Prev
- 1
- Next